3 research outputs found
Cerebrospinal fluid abnormalities in first- and multi-episode schizophrenia-spectrum disorders: impact of clinical and demographical variables
Multiple lines of evidence indicate that immunological and inflammatory alterations contribute at least in a subgroup to the pathophysiology of schizophrenia. In this retrospective chart review, we investigated whether clinical factors contribute to altered cerebrospinal fluid (CSF) findings in schizophrenia-spectrum disorders. Clinical data from electronic medical records of patients with psychotic disorders (ICD-10: F20-F29) who received routine CSF diagnostics at the Department of Psychiatry and Psychotherapy, LMU Munich, Germany, were included. ChiÂČ tests for dichotomous outcomes and independent t tests for continuous outcomes were used to compare differences between groups. A total of 331 patients were included in the analyses (43.2% female and 56.8% male). The mean age was 37.67 years (±15.58). The mean duration of illness was 71.96 months (±102.59). In all, 40% (128/320) were first-episode psychosis (FEP) patients and 60% (192/320) were multi-episode psychosis (MEP) patients. Elevated CSF protein levels were found in 19.8% and elevated CSF/serum albumin ratios (Q(Alb)) in 29.4% of the cases. Pleocytosis was found in 6.1% of patients. MEP patients showed significantly higher mean Q(Alb) compared with FEP patients (t((304.57))â=ââ2.75, pâ=â0.006), which did not remain significant after correcting for age. Q(Alb) elevation occurred more frequently in men (X(2)((1))â=â14.76, pâ=â<0.001). For treatment resistance, family history, and cMRI alterations, no significant differences in CSF-related outcomes were detected. Our work extends other retrospective cohorts confirming a relevant degree of CSF alterations in schizophrenia-spectrum disorders and shows the difficulty to relate these alterations to clinical and disease course trajectories. More research is needed to develop treatment response predictors from CSF analyses
High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion
Abstract A deeper understanding of COVIDâ19 on human molecular pathophysiology is urgently needed as a foundation for the discovery of new biomarkers and therapeutic targets. Here we applied mass spectrometry (MS)âbased proteomics to measure serum proteomes of COVIDâ19 patients and symptomatic, but PCRânegative controls, in a timeâresolved manner. In 262 controls and 458 longitudinal samples of 31 patients, hospitalized for COVIDâ19, a remarkable 26% of proteins changed significantly. Bioinformatics analyses revealed coâregulated groups and shared biological functions. Proteins of the innate immune system such as CRP, SAA1, CD14, LBP, and LGALS3BP decreased early in the time course. Regulators of coagulation (APOH, FN1, HRG, KNG1, PLG) and lipid homeostasis (APOA1, APOC1, APOC2, APOC3, PON1) increased over the course of the disease. A global correlation map provides a systemâwide functional association between proteins, biological processes, and clinical chemistry parameters. Importantly, five SARSâCoVâ2 immunoassays against antibodies revealed excellent correlations with an extensive range of immunoglobulin regions, which were quantified by MSâbased proteomics. The highâresolution profile of all immunoglobulin regions showed individualâspecific differences and commonalities of potential pathophysiological relevance